Orchestra BioMed
OBIO
24 hedge funds and large institutions have $56.6M invested in Orchestra BioMed in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
4% more funds holding
Funds holding: 23 → 24 (+1)
0% more capital invested
Capital invested by funds: $56.4M → $56.6M (+$228K)
0.38% less ownership
Funds ownership: 50.8% → 50.43% (-0.38%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCWM
Graham Capital Wealth Management
Washington D.c.,
District of Columbia
|
+$647K |
| 2 |
PCM
PenderFund Capital Management
Vancouver,
British Columbia, Canada
|
+$550K |
| 3 |
SFM
Spartan Fund Management
Toronto, Ontario,
Canada
|
+$266K |
| 4 |
RL
RPO LLC
Stamford,
Connecticut
|
+$35.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$1.49M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$386K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$28K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$13.4K |
| 5 |
Morgan Stanley
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Morgan Stanley
New York
| – | -$1K | -100 | Closed |
|
OBIO Hedge Fund Activity: Q4 2022 in Review
24 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q4 2022, worth a combined $56.6M — up 0.4% from $56.4M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new OBIO positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Graham Capital Wealth Management, opening a new position worth an estimated $647K. The largest seller was Boxer Capital, cutting an estimated $1.49M.
- 24 institutional investors held Orchestra BioMed (OBIO) as of Q4 2022, up from 23 in Q3 2022.
- Funds reported $56.6M of Orchestra BioMed stock for Q4 2022, up 0.4% quarter-over-quarter.
- 3 funds opened new Orchestra BioMed positions in Q4 2022 and 2 closed out, a net change of +1 holder.
- The largest Orchestra BioMed buyer in Q4 2022 was Graham Capital Wealth Management, an estimated $647K added.
- The largest Orchestra BioMed seller in Q4 2022 was Boxer Capital, an estimated $1.49M sold.
Based on aggregated 13F filings for Q4 2022.